Navigation Links
Phase III data show investigational compound empagliflozin significantly reduced blood glucose in adults with type 2 diabetes
Date:6/22/2013

RIDGEFIELD, Conn. and INDIANAPOLIS, June 22, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announced two late-breaking presentations with results from a pooled analysis of four pivotal phase III trials of the investigational agent empagliflozin* in people with type 2 diabetes (T2D).

In the pooled analysis, presented at the American Diabetes Association 73rd Scientific Sessions®, people with T2D treated with empagliflozin versus placebo achieved significant reductions in HbA1c, fasting plasma glucose (FPG), weight and blood pressure after 24 weeks.1 In the same analysis, people treated with empagliflozin vs. placebo experienced an increased frequency of genital infections, but not urinary tract infections (UTIs).2

Empagliflozin is a member of the sodium glucose co-transporter-2 (SGLT2) inhibitor class of compounds, and is being investigated for the reduction of blood glucose levels in adults with T2D. The emerging SGLT2 inhibitor class removes excess glucose through the urine by blocking glucose re-absorption by the kidney.

"We are primarily encouraged by the blood sugar lowering results seen in this analysis," said Christophe Arbet-Engels, PhD, vice president, metabolic-clinical development and medical affairs, Boehringer Ingelheim Pharmaceuticals, Inc. "People with type 2 diabetes face different challenges. Many of them are not meeting their blood sugar level goals and have difficulties managing other factors such as weight and increased blood pressure."

About Posters #69-LB and #74-LB
Both posters are based on pooled data from 2,477 people with T2D who participated in one of four randomized, placebo-controlled phase III trials that investigated empagl
'/>"/>

SOURCE Eli Lilly and Company; Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Follow-up Phase II Data Analysis Adds to Body of Evidence for Investigational Novel Basal Insulin, LY2605541
2. Phase III data show significant reduction in blood glucose with investigational compound empagliflozin added to metformin or metformin plus sulfonylurea in adults with type 2 diabetes
3. Sanofi Announces Positive Phase 3 Data for Once-Daily Lixisenatide for Type 2 Diabetes
4. Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine
5. Safinamide Phase III Study Results Presented at 2013 MDS Meeting
6. Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinsons Disease
7. Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder
8. AbbVie Presents Preliminary Results from Phase I Study of Investigational Oncology Compound ABT-199/GDC-0199 in Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) at European Hematology Association Annual Meeting
9. Updated Results of Two Phase 2 Ibrutinib Studies in Patients with Mantle Cell Lymphoma or Diffuse Large B-cell Lymphoma
10. Ibrutinib Phase 2 Data: Analyses Show Efficacy with Ibrutinib Monotherapy in Patients with Relapsed or Refractory Mantle Cell or Diffuse Large B-cell Lymphoma
11. Lilly Voluntarily Terminates Phase II Study for LY2886721, a Beta Secretase Inhibitor, Being Investigated as a Treatment for Alzheimers Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/30/2015)... Massachusetts y LONDRES, August 30, 2015 /PRNewswire/ ... ofrece una visión holística de l ... todo el trayecto   ... hoy el debut europeo de IntelliSpace Cardiovascular , ... que ofrece sofisticadas herramientas para acceder, analizar y compartir ...
(Date:8/28/2015)... , Aug. 28, 2015  Delays in ... projects can slow down the decision-making process, resulting ... therefore, absolutely critical for biopharmaceutical companies to develop ... approval process for quicker and more meaningful insights. ... Best Practices, LLC, nearly three-quarters of benchmarked study ...
(Date:8/28/2015)... , Aug. 28, 2015 ... announced the addition of the "Investigation Report ... their offering. Originally discovered by Welfide ... Pharmaceutical Industries, Ltd) as an inflammatory drug, pranoprofen ... Pharmaceutical Co., Ltd under the trade name of ...
Breaking Medicine Technology:Philips presenta IntelliSpace Cardiovascular en el Congreso ESC 2015 2Philips presenta IntelliSpace Cardiovascular en el Congreso ESC 2015 3Expediting the Pharmaceutical Market Research Process for Faster Insights 2Investigation Report on China's Pranoprofen Market, 2010-2019 2
... NEW YORK, April 28, 2011 Reportlinker.com ... is available in its catalogue: ... Healthcare System and Drug Regulatory Overview: Cost-containment ... http://www.reportlinker.com/p0487111/Pharmaceutical-Key-Trends-2011---Healthcare-System-and-Drug-Regulatory-Overview-Cost-containment-and-regulatory-pressures-intensify.html ...
... 28, 2011 West Pharmaceutical Services, Inc. (NYSE: ... quarter of 2011.  Summary comparative results were as follows:($ millions, ... 295.4 , $ 274.7Gross Profit , 88.0 , 82.2Reported Operating ... 30.7 , 29.5Reported Diluted EPS , $ 0.56 , $ ...
Cached Medicine Technology:Reportlinker Adds Pharmaceutical Key Trends 2011 - Healthcare System and Drug Regulatory Overview: Cost-containment and regulatory pressures intensify 2Reportlinker Adds Pharmaceutical Key Trends 2011 - Healthcare System and Drug Regulatory Overview: Cost-containment and regulatory pressures intensify 3Reportlinker Adds Pharmaceutical Key Trends 2011 - Healthcare System and Drug Regulatory Overview: Cost-containment and regulatory pressures intensify 4Reportlinker Adds Pharmaceutical Key Trends 2011 - Healthcare System and Drug Regulatory Overview: Cost-containment and regulatory pressures intensify 5Reportlinker Adds Pharmaceutical Key Trends 2011 - Healthcare System and Drug Regulatory Overview: Cost-containment and regulatory pressures intensify 6West Announces First Quarter 2011 Results 2West Announces First Quarter 2011 Results 3West Announces First Quarter 2011 Results 4West Announces First Quarter 2011 Results 5West Announces First Quarter 2011 Results 6West Announces First Quarter 2011 Results 7West Announces First Quarter 2011 Results 8West Announces First Quarter 2011 Results 9West Announces First Quarter 2011 Results 10West Announces First Quarter 2011 Results 11West Announces First Quarter 2011 Results 12West Announces First Quarter 2011 Results 13West Announces First Quarter 2011 Results 14
(Date:8/31/2015)... Scotch Plains, NJ (PRWEB) , ... August 31, ... ... in practice! Garden State Urology was formed in 2008, the result of a ... on the principle that by working cooperatively, they could provide more cost-effective and ...
(Date:8/31/2015)... , ... August 31, 2015 , ... NJ Top Docs Presents, Dr. Michael Betsy! ... in Park Ridge, New Jersey, Dr. Michael Betsy graduated from Don Bosco Prep in 1990 ... served as team captain in both sports in his senior year. He was inducted ...
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... Dr. ... it may be prevented during Amblyopia Awareness Month. Only a comprehensive eye examination can ... most common cause of visual impairment among children, affecting approximately 2 to 3 out ...
(Date:8/31/2015)... ... August 31, 2015 , ... Diablo Publications ... today that it has officially launched a new website and company identity ( ... refresh are more closely aligned with the company’s strategic vision for growth and ...
(Date:8/31/2015)... Moscow, PA (PRWEB) , ... August 31, 2015 , ... ... to provide visitors and retailers with even more relevant and easy-to-find information on their ... , “Our website has always been an important way for us to share ...
Breaking Medicine News(10 mins):Health News:NJ Top Docs Presents, Garden State Urology! 2Health News:NJ Top Docs Presents, Dr. Michael Betsy! 2Health News:NJ Top Docs Presents, Dr. Michael Betsy! 3Health News:Renowned Eye Surgeon Dr. Stewart Shofner Shares Information about the Causes of Lazy Eye During Amblyopia Awareness Month 2Health News:Renowned Eye Surgeon Dr. Stewart Shofner Shares Information about the Causes of Lazy Eye During Amblyopia Awareness Month 3Health News:Diablo Publications Launches New Company Website 2Health News:Diablo Publications Launches New Company Website 3Health News:Three Bakers Gluten Free Bakery Announces Launch of New Website 2
... fare more likely to act out at 7, 10, study ... exposed to violent television -- even cartoons -- are more ... Their findings don,t definitively prove that TV makes children act ... to the researchers. But the link does appear solid in ...
... ORLANDO, Fla. -- If you go to the hospital within ... a heart attack, your chances of getting proper treatment are ... 12 hours before seeking treatment, according to results presented today ... Fla. , This research should emphasize to patients that getting ...
... For the next two weeks,the "Help is Here ... of Southern California, attempting to help uninsured and,under-insured ... stop will,be from 10 a.m. until 2 p.m. ... CA., This marks the seventh time the ...
... Nov. 5 /PRNewswire/ - Halogen Software Inc., the ... software,today announced the third quarter of 2007 was ... in almost every category with nearly,50 percent year-over-year ... "Maximizing employee performance is a high priority ...
... role for a cancer-prevention gene in the response to drug ... suppressor gene, also known as the guardian of the genome, ... Mutations in the gene are associated with a high incidence ... give rise to tumours. , In childhood cancers such as ...
... , , MONDAY, Nov. 5 (HealthDay News) -- It turns out ... control in colder weather, heart experts say. , But the ... Association annual meeting, in Orlando, Fla., is not exactly new. ... pressure tends to be a little bit harder to control ...
Cached Medicine News:Health News:TV Violence May Spur Aggression in Boys 2Health News:TV Violence May Spur Aggression in Boys 3Health News:Mayo Clinic identifies new risk factor for heart attack patients 2Health News:'Help is Here Express' Bus Tour in California to Help Fire Victims Access Prescription Medicines 2Health News:'Help is Here Express' Bus Tour in California to Help Fire Victims Access Prescription Medicines 3Health News:Halogen Software Achieves Most Successful Quarter in Company History - Includes Record Year-Over-Year Overall and License Revenue 2Health News:Halogen Software Achieves Most Successful Quarter in Company History - Includes Record Year-Over-Year Overall and License Revenue 3Health News:Blood Pressure Tougher to Tame in Winter 2
The Plasma Extractor is used to express blood components from collection containers. The spring-loaded front panel exerts pressure on the collection container causing the fluid to transfer until cont...
The Eppendorf Maxipettor is a continuously adjustable pipette for precise pipetting of volumes up to 10 ml (in 10 l increments). Even liquids with a high vapor pressure or viscosity can be pipetted w...
... only catheter of its kind, the ... collects real-time cardiac electrical information, translating ... With 64 electrodes, this unique tool ... than 3,000 points of electrical data ...
... The St. Jude Medical® Pacing System Analyzer ... solution for implantation testing, programming and interrogation ... as an easy-to-use accessory to the St. ... testing by obtaining measurements of intrinsic P- ...
Medicine Products: